Call Us Today @ 0172 - 4680800 | info@indswift.com | NSE - BSE
Drug for pancreatic cancer developed by college of pharmacy researchers
 
A treatment for highly aggressive and commonly fatal pancreatic cancer is being developed, reports a University of Houston researcher who has designed a new medicine that can inhibit two of the major pathways of the deadly disease. Ruiwen Zhang, M.D., Ph.D. and Robert L. Boblitt Endowed Professor in Drug Discovery, has published his findings, along with research associate professor of pharmacology Wei Wang, M.D., Ph.D., in Cancer Research Journal.

"There is an unmet clinical need for new, effective and safe drugs for pancreatic cancer therapy. Our discovery represents a significant advance in cancer research," said Zhang. "Most drugs only target one factor. We identified a single compound that targets two linked genes that cause cancer."

The drug would be a first-in-class, new therapy for pancreatic cancer and a new conceptual framework for developing other drugs.

Pancreatic cancer is characterized by early metastasis and a poor response to chemotherapy. Gemcitabine, a chemotherapy drug with only modest clinical benefit, remains one of the mainstays of treatment for advanced pancreatic cancer. Although various multidrug regimens that combine gemcitabine with other chemotherapeutic or molecular-targeted agents have been evaluated, only three combination regimens have been approved by the Food and Drug Administration, and most of them failed to significantly prolong the survival of patients with pancreatic cancer in clinical trials. Stromal depletion and immunotherapy also have been proposed to offer substantial promise for treating advanced pancreatic cancer, but their therapeutic impact remains unclear.
The two cancer-causing genes linked in pancreatic cancer are nuclear factor of activated T cells1 (NFAT1) and murine double minute 2 (MDM2), a gene that regulates (and depletes) the tumor su
ppressor gene called p53. If there is no tumor suppressor p53 present, MDM2 will cause cancer on its own. NFAT1 up-regulates MDM2 expression and encourages tumor growth.
"We developed a synthetic compound that we call MA242, and it can deplete both proteins at the same time increasing specificity and efficiency of tumor killing," said Zhang. "In our molecular modeling study, MA242 is a potent dual inhibitor." Though it is man-made, the new compound is based on a type of sea sponge.

Patients with pancreatic cancer have too much MDM2 and NFAT1, which has left these genes as open targets for cancer therapy. Numerous studies have shown reduced MDM2 can lead to decreased tumor growth and progression.
Heathy individuals have low levels of MDM2 and NFAT1, but diet, nutrition and environment can cause higher levels in cells, said Zhang. In previously published work, Zhang revealed that certain natural foods and products, like broccoli, soybeans, green tea and turmeric, have shown potential for cancer prevention and therapy.

(WORDPHARMANEWS)
 
Other Related News:
Drug for pancreatic cancer developed by college of pharmacy researchers
FDA approves new kind of treatment for hairy cell leukemia
Dietary fiber reduces brain inflammation during aging
Special antibodies could lead to HIV vaccine
Breakthrough sensor to help people with bipolar disorder monitor lithium levels
Drug could aid recovery after a heart attack
Researchers identify potential new target for malaria drug development
Indo-China talks put on fast track to bring down drug approval timeline & import tariff on priority therapeutics
Brains installs Ziehm Hybrid Intra-operative Imaging System to enable accurate spinal surgeries
Early type 1 diabetes shortens women's lives by 18 years